Gastrointestinal and Fluorouracil


Gastrointestinal Symptoms and Causes

When you eat, your body breaks food down to a form it can use to build and nourish cells and provide energy. This process is called digestion.

Your digestive system is a series of hollow organs joined in a long, twisting tube. It runs from your mouth to your anus and includes your esophagus, stomach, and small and large intestines. Your liver, gallbladder and pancreas are also involved. They produce juices to help digestion.

There are many types of digestive disorders. The symptoms vary widely depending on the problem. In general, you should see your doctor if you have

  • Blood in your stool
  • Changes in bowel habits
  • Severe abdominal pain
  • Unintentional weight loss
  • Heartburn not relieved by antacids

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Check out the latest treatments for gastrointestinal

gastrointestinal treatment research studies

Fluorouracil clinical trials, surveys and public health registries

Find Drug Side Effect reports

Fluorouracil Side Effects

Diarrhoea (463)
Nausea (335)
Dehydration (273)
Vomiting (266)
Neutropenia (243)
Febrile Neutropenia (207)
Pyrexia (187)
Mucosal Inflammation (179)
Asthenia (158)
Abdominal Pain (152)
Stomatitis (143)
Fatigue (134)
Dyspnoea (131)
Interstitial Lung Disease (117)
Decreased Appetite (116)
Pulmonary Embolism (111)
Chest Pain (110)
Anaemia (106)
Thrombocytopenia (106)
Hypotension (106)
Neutrophil Count Decreased (99)
Hypokalaemia (95)
Leukopenia (83)
Sepsis (78)
White Blood Cell Count Decreased (78)
Renal Failure Acute (75)
Pneumonia (75)
Malaise (74)
Haemoglobin Decreased (72)
Neuropathy Peripheral (69)
Pain (69)
Renal Failure (64)
Disease Progression (64)
Respiratory Failure (62)
Cardiotoxicity (62)
Dysphagia (61)
Confusional State (57)
Platelet Count Decreased (57)
Pancytopenia (55)
Fall (55)
Deep Vein Thrombosis (54)
Myocardial Infarction (53)
Arteriospasm Coronary (51)
Hyponatraemia (51)
Weight Decreased (51)
Tachycardia (48)
Chills (46)
Dizziness (46)
Septic Shock (46)
Hyperammonaemia (46)

➢ More

Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)

Recent Reviews

Why do doctors keep the availabilty of the test for DPD deficiency a secret??? My sister is a doctor, infectious disease, at St Francis in Charleston, SC. Our father was treated by an oncologist well known to my sister, a 'colleague' you might s

After a gi bleed dont feel like eating just makes me feel sick

I have hypocalcaemea necrosis. I have been suffering this for 7 years and need to walk with crutches.

Its not 1%---more like 14% and that may even be a conservative estimate--Your doctor is lieing to you--surprised???

My fiancee passed away on 3/7/2011 after her second round of 5FU. The oncologist had used the words 'surprised' and 'out of the ordinary' on her reaction to the first round because of the amount and severity of her side effects. H

Actuallly the risk of a gastrointestinal bleeding is increased with Pradaxa compared to Warfarin, there isalso an interaction withVerapamil leading to higher plama levels of Pradaxa.

Gastrointestinal. Severe pain starting in middle of chest and wrapping around to middle of back. Tests showed inflamation in stomach and I am now on a bland diet indefinately. Also had trouble swallowing pills and food.&

I am currently involve in a case study about hypercholesterilemia, our patient was given Niacin and Cholestyramine resin(Questran) it was stop because the patient cannot tolerate the flushing and gastrointestinal effects bought by this drugs and repl

I had funny gastrointestinal feelings. Almost as if balloons were popping in my stomach. I had the urge to stool but only the flatulence sound---no stools. I always felt so 'empty' even though I was eating regularly. I stopped at three days I couldn'

I have had Aclasta infusions twice now. On both occasions I experienced gastrointestinal symptoms but three weeks later. One time, it was very acute, right lower quadrant pain, and this year it has been cramps and diarrhea. First time, I felt unwell

I received a dose on May 12 and May 13, 2010 that Friday on May16 i got a really violent headache. By Saturday, I ended up with terrible sweating, fatigue, gastrointestinal problems. On Sunday more of the same. Monday st

I take Vastarel MR once a day. Tired, gastrointestinal increase

I was diagnosed with diabetes 2 years ago and have been taking one diabex xr tablet per day with dinner . Since then I have had gastrointestinal problems which only ease with gastro stop tabletswhen needed. I am frightened to goan

I was diagnosed with diabetes 2 years ago. I take one tablet a day with dinner, Since taking diabex I have cramps, and diarrea and gastrointestinal problems . My life is becoming a series of toilet seeking on journeys and I hate travelling. Could thi

On Nov 3 2010 I had my first and last injection. It nearly killed me. the 4th I felt like i had the flu and layed around. The 5th I felt worse, really yucky, and on the 6th I had to be taken 911 to the hospital. I had a gastrointestinal bleed. which

Gastrointestinal Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Unknown  ESTD vs. VATS for Upper Gastrointestinal Submucosal Tumors
Conditions: Upper Gastrointestinal Submucosal Tumors (SMTs);   Gastrointestinal Stromal Tumors (GISTs);   Leiomyoma
Interventions: Procedure: ESTD;   Procedure: VATS
Outcome Measures: En bloc resection;   Curative resection;   Procedure related complication;   Short-term morbidity;   Local recurrence;   Quality of life
2 Recruiting Evaluation of People With Gastrointestinal Disease
Condition: Gastrointestinal Diseases
Outcome Measures: Evaluate patients with Gastrointestinal disorders.;   During a clinically indicated standard of care test or procedure, allow for donation of extra stool, urine, blood, gastric aspirate or Gastrointestinal tissue sample for collection and storage.;   Allow outpatient evaluation and follow-up of patients with a variety of Gastrointestinal diseases for the purposes of physician education in the NIDDK accredited gastroenterology training program.
3 Recruiting Occult Gastrointestinal Bleeding in Non-pulsatile Left Ventricular Assist Device(VAD)Patients
Conditions: Gastrointestinal Bleeding;   Complication of Internal Device
Outcome Measures: Proportion of VAD Patients with Gastrointestinal Bleeding as Assessed by HemoQuant Fecal Occult Blood Testing;   Examine Behavior of Gastrointestinal Bleeding in VAD Patients By Estimating the Proportion of VAD Patients with an Abnormal HemoQuant Test Prior to Implantation
4 Recruiting Acquisition of Blood and Tumor Tissue Samples From Patients With Gastrointestinal Cancer
Conditions: Gastrointestinal Neoplasms;   Cancer of Gastrointestinal Tract;   Cancer of the Gastrointestinal Tract;   Gastrointestinal Cancer;   Neoplasms, Gastrointestinal
Outcome Measure:
5 Recruiting EUS-FNA Versus KHB in Diagnostics of Upper Gastrointestinal Submucosal Tumors
Condition: Other Specified Disorders of Esophagus, Stomach or Duodenum
Interventions: Procedure: Key Hole Biopsy ( KHB);   Procedure: EUS-FNA
Outcome Measures: To compare the yield and success of KHB and EUS-FNA in cytological / histological and immunohistochemical diagnostics of Upper Gastrointestinal Submucosal Tumors.;   Detection of mitotic activity in case of Gastrointestinal Stromal Tumors
6 Not yet recruiting An International, Multicentric, Prospective, Observational Study to Evaluate Monosyn® Suture Material for Anastomoses in the Gastrointestinal Tract
Conditions: C.Surgical Procedure; Digestive System;   Symptomatic Disorders of the Gastrointestinal Tract;   Gastric Anastomosis (Site);   Gastrointestinal Neoplasms
Intervention: Device: Monosyn
Outcome Measures: Frequency of anastomosis leakage rate;   Postoperative complication rate;   Reoperation rate;   Length of hospital stay;   Stay in the intensive care unit;   Duration to perform the anastomosis;   Cost;   Handling of the device
7 Not yet recruiting Gastrointestinal Tolerability Study Of Dimethyl Fumarate (DMF) In Participants With Relapsing-Remitting Multiple Sclerosis In Germany
Condition: Relapsing-Remitting Multiple Sclerosis
Intervention: Drug: BG00012
Outcome Measures: Incidence Of Gastrointestinal-Related Events In Participants Who Utilize Symptomatic Therapy During The 12-Week Treatment Period;   Severity Of Gastrointestinal -Related Events In Participants Who Utilize Symptomatic Therapy During The 12-Week Treatment Period;   Duration Of Gastrointestinal -Related Events In Participants Who Utilize Symptomatic Therapy During The 12-Week Treatment Period;   Percentage Of Participants Requiring Gastrointestinal Symptomatic Therapy During The 12-Week Treatment Period;   Number of Participants Who Used Symptomatic Therapies for Gastrointestinal -Related Events During the 12-Week Treatment Period;   Duration of Use of Symptomatic Therapies for Gastrointestinal -Related Events During the 12-Week Treatment Period;   Kaplan-Meier Estimates for the Proportion of Participants Who Require BG00012 Dose Reduction In Response To Gastrointestinal -Related Events;   The Percentage of Participants Who Discontinue BG00012 Due To Gastrointestinal -Related Events
8 Recruiting Cognitive Behavior Therapy (CBT) for Children With Functional Gastrointestinal Disorders
Conditions: Functional Gastrointestinal Disorders (FGID);   FGID According to the Rome III Criteria;   Irritable Bowel Syndrome (IBS);   Functional Abdominal Pain;   Functional Dyspepsia
Intervention: Other: Cognitive behavior therapy
Outcome Measures: Change in Faces Pain Rating Scale (FACES) from baseline to 10 weeks;   Change in Faces Pain Rating Scale (FACES) from baseline to 8 months.;   Change in Gastrointestinal Symptom Rating Scale (GSRS-IBS) from baseline to 10 weeks.;   Change in Children´s Somatization Inventory (CSI 24) from baseline to 10 weeks;   Change in Gastrointestinal Symptom Scale (PedsQL Gastro) from baseline to 10 weeks;   Change in Functional Disability Index (FDI) from baseline to 10 weeks.;   Change in Pain Reactivity Scale from baseline to 10 weeks.;   Change in IBS-behavioral responses questionnaires (IBS-BRQ) from baseline to 10 weeks.;   Change in Spence Children Anxiety Scale (SCAS) from baseline to 10 weeks.;   Change in Child Depression Inventory (CDI) from baseline to 10 weeks.;   Change in Pain Interference Index (PII) from baseline to 10 weeks.;   Change in Pediatric Quality of Life Inventory (Peds QL) from baseline to 10 weeks.;   Change in Gastrointestinal Symptom Rating Scale (GSRS-IBS) from baseline to 8 months.;   Change in Children´s Somatization Inventory (CSI 24) from baseline to 8 months;   Change in Gastrointestinal Symptom Scale (PedsQL Gastro) from baseline to 8 months.;   Change in Functional Disability Index (FDI) from baseline to 8 months.;   Change in IBS-behavioral responses questionnaires (IBS-BRQ) from baseline to 8 months.;   Change in Spence Children Anxiety Scale (SCAS) from baseline to 8 months.;   Change in Child Depression Inventory (CDI) from baseline to 8 months.;   Change in Pain Interference Index (PII) from baseline to 8 months.;   Change in Pediatric Quality of Life Inventory (Peds QL) from baseline to 8 months.;   Change in Pain Reactivity Scale from baseline to 8 months.
9 Unknown  Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer
Conditions: Bladder Cancer;   Cervical Cancer;   Colorectal Cancer;   Endometrial Cancer;   Gastrointestinal Complications;   Long-term Effects Secondary to Cancer Therapy in Adults;   Ovarian Cancer;   Prostate Cancer;   Radiation Toxicity;   Sarcoma;   Testicular Germ Cell Tumor;   Vaginal Cancer
Interventions: Other: questionnaire administration;   Procedure: Gastrointestinal complications management/prevention;   Procedure: quality-of-life assessment
Outcome Measures: Gastrointestinal symptoms score using the IBDQ quality-of-life questionnaire;   Physician assessment of adverse effects using LENT SOMA scales of radiation injury;   Patient self-assessments using EORTC QLQ-C30 and Defecation Problem Subscale of QLQ-CR38;   Photographic images of rectal mucosa;   Physician assessment of rectal dysfunction based on the modified CTCAE grading system;   Health economics data
10 Recruiting Development of Early Detection Signs for Gastrointestinal Cancer
Condition: GI Cancer
Intervention: Other: Specimen bank
Outcome Measures: The first goal of this proposal is to collect cells from the peripheral blood, tumor draining lymph nodes and tumor infiltrating lymphocytes in patients with early or late stage Gastrointestinal cancers.;   The second goal is to evaluate using novel proteomic, CellomicTM, and genomic techniques the serum and peripheral blood lymphocytes of these patients for protein, cellular changes and genetic markers that correlate with the presence of cancer.
11 Recruiting A Study to Assess the Role of a Gluten Free-dairy Free (GFCF) Diet in the Dietary Management of Autism Associated Gastrointestinal Disorders
Conditions: Autism;   Gastrointestinal Symptoms
Interventions: Other: GFCF product with GFCF diet;   Other: product containing gluten and casein (milk protein) with GFCF diet
Outcome Measure: A study to assess the role of a gluten free-casein free diet in the dietary management of autism associated Gastrointestinal disorders
12 Recruiting Intervention to Motivate Standing &Walking in Gastrointestinal Cancer Surgical Patients
Condition: Gastrointestinal Neoplasms
Intervention: Behavioral: Education/Daily Planning
Outcome Measures: Percentage of patients with diagnosed Gastrointestinal cancer who showed daily compliance using activity monitors and tablet computers to measure physical activity.;   Percentage of patients with a diagnosis of Gastrointestinal cancer that benefit from an intervention of physical activity daily planning and education.
13 Not yet recruiting Efficacy and Safety of PD-0332991 in Patients With Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib
Condition: Advanced Gastrointestinal Stromal Tumors
Intervention: Drug: PD-0332991 will be administrated orally, formulated as gelatin capsules of 100 mg and 25 mg respectively.
Outcome Measures: Efficacy assessment of PD-0332991;   Objective response;   Progression-free survival;   Overall survival;   Progression;   Safety of PD-0332991
14 Recruiting Effects of the Administration of Ornithine Phenylacetate in Patients With Cirrhosis and Upper Gastrointestinal Bleeding
Conditions: Gastrointestinal Bleeding;   Cirrhosis
Intervention: Drug: Ornithine-phenylacetate
Outcome Measures: Ammonia plasma concentration umol/L.;   Hepatic encephalopathy
15 Recruiting A Study to Evaluate the Safety and Tolerability of MEDI-565 in Adults With Gastrointestinal Adenocarcinomas
Condition: Gastrointestinal Adenocarcinomas
Intervention: Drug: MEDI-565
Outcome Measures: Determine the maximum tolerable dose (MTD) or optimal biological dose (OBD) of MEDI-565 in subjects with Gastrointestinal (GI) adenocarcinomas for which no standard or curative treatments are available.;   Evaluate the safety profile in adult subjects with advanced Gastrointestinal (GI) adenocarcinomas who have no available standard or curative treatments.;   Assess the safety and antitumor activity of MEDI-565 in the dose-expansion phase.;   Pharmacokinetics of MEDI-565;   Immunogenicity of MED-565
16 Recruiting ELIGIBLE (Efficacy of Left atrIal Appendage Closure After Gastrointestinal BLEeding)
Condition: Adverse Reaction to Drugs Affecting the Gastrointestinal System
Intervention: Device: Left atrial appendage occlusion
Outcome Measure: Combined overall mortality, major bleeding, stroke or procedure-related complications
17 Recruiting Adverse Events During Upper Gastrointestinal Endoscopy
Conditions: Patients Need Upper Gastrointestinal Endoscopy;   Peptic Ulcer;   Gastric Cancer;   Esophagus Cancer;   Oesophagitis
Outcome Measure: Adverse events
18 Recruiting The Impact of Rockall Risk Scoring System on Management of Upper Gastrointestinal System Bleeding
Condition: Gastrointestinal Hemorrhage
Intervention: Procedure: Gastroscopy
Outcome Measures: The necessity of emergency endoscopy.;   Morbidity;   Mortality;   Length of hospital stay
19 Not yet recruiting The Use of Hexacapron in Upper Gastrointestinal Bleeding
Conditions: Upper Gastrointestinal Bleeding;   Hexacapron;   Hemostasis;   Rebleeding;   Mortality
Interventions: Drug: Hexacapron( Tranexamic acid);   Drug: esomeprazole
Outcome Measures: Prevention of rebleeding manifested as hematemesis, melena and drop in hemoglobin level by 2g% within 24 hours after therapeutic endoscopy;   Rebleeding, need for surgery , 30 day mortality
20 Recruiting Erythromycin Versus Gastric Lavage to Improve Quality of Endoscopy in Patients With Upper Gastrointestinal Bleeding
Conditions: Gastrointestinal Hemorrhage;   Hematemesis
Interventions: Drug: Erythromycin;   Procedure: gastric lavage
Outcome Measures: Visual quality of endoscopy;   need for a second-look endoscopy;   need of blood transfusion;   number of adverse events as a measure of safety and tolerability;   length of hospitalisation;   length of endoscopic procedure;   need for arteriography or surgery